90Y-labelled anti-CD22 epratuzumab tetraxetan in adults with refractory or relapsed CD22-positive B-cell acute lymphoblastic leukaemia: a phase 1 dose-escalation study

The Lancet Haematology

Volumn 2, Issue 3, 2015, Pages e108-e117

  Chevallier, Patrice ^a   Eugene, Thomas ^b   Robillard, Nelly ^b   Isnard, Françoise ^c   Nicolini, Franck ^d   Escoffre Barbe, Martine ^e   Huguet, Françoise ^f   Hunault, Mathilde ^g   Marcais, Antoine ^h   Gaschet, Joelle ^i,j   Cherel, Michel ^i,j,k,l   Guillaume, Thierry ^a   Delaunay, Jacques ^a   Peterlin, Pierre ^a   Eveillard, Marion ^b   Thomas, Xavier ^d   Ifrah, Norbert ^g   Lapusan, Simona ^c   Bodet Milin, Caroline ^b,i,j   Barbet, Jacques ^i,j,l   Faivre Chauvet, Alain ^b,i,j   Ferrer, Ludovic ^i,k   Bene, Marie C ^b   Le Houerou, Claire ^a   Goldenberg, David M ^m   Wegener, William A ^m   Kraeber Bodéré, Françoise ^b,i,j,k   more..

^a HÔTEL DIEU   (France)

^b NANTES UNIVERSITY HOSPITAL   (France)

^c ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

^d HOSPICES CIVILS DE LYON   (France)

^e RENNES UNIVERSITY HOSPITAL   (France)

^f La Croix du Sud Hospital   (France)

^g ANGERS UNIVERSITY HOSPITAL   (France)

^h HÔPITAL NECKER ENFANTS MALADES   (France)

ⁱ CNRS   (France)

^j UNIVERSITÉ DE NANTES   (France)

^k UMR INSERM U892 CNRS 6299   (France)

^l GIP ARRONAX   (France)

^m Immunomedics   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CD22 ANTIGEN; CORTICOSTEROID; DEXCHLORPHENIRAMINE MALEATE; EPRATUZUMAB; EPRATUZUMAB TETRAXETAN YTTRIUM Y 90; FLT3 LIGAND; INDIUM 111; PARACETAMOL; TETRAXETAN; YTTRIUM CHLORIDE Y 90; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY; YTTRIUM;

ABDOMINAL PAIN; ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; AGED; APLASIA; ARTICLE; ASTHENIA; BACTERIAL INFECTION; BLOOD SAMPLING; BONE MARROW APLASIA; CANCER RECURRENCE; CLINICAL ARTICLE; CONSTIPATION; DISEASE FREE SURVIVAL; DOSIMETRY; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG TOLERABILITY; DYSPEPSIA; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FEVER; FLOW CYTOMETRY; HEMORRHOID; HUMAN; HYPERKALEMIA; HYPERURICEMIA; HYPOTENSION; INFECTION; ISOTOPE LABELING; KARYOTYPE; LUNG EDEMA; MALE; MINIMAL RESIDUAL DISEASE; MYCOSIS; NAUSEA; ODYNOPHAGIA; OVERALL SURVIVAL; PAIN; PANCYTOPENIA; PHASE 1 CLINICAL TRIAL; PHILADELPHIA CHROMOSOME POSITIVE CELL; PRIORITY JOURNAL; PROSPECTIVE STUDY; PRURITUS; RADIATION DOSE; RADIOIMMUNOTHERAPY; RASH; REAL TIME POLYMERASE CHAIN REACTION; SCINTIGRAPHY; SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY-COMPUTED TOMOGRAPHY; THROMBOSIS; URINARY TRACT INFECTION; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL; FRANCE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; PRECURSOR B-CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; TREATMENT OUTCOME;

ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; FEMALE; FRANCE; HUMANS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; PRECURSOR B-CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROSPECTIVE STUDIES; RADIOIMMUNOTHERAPY; SIALIC ACID BINDING IG-LIKE LECTIN 2; TREATMENT OUTCOME; YTTRIUM RADIOISOTOPES;

EID: 84958762690     PISSN: None     EISSN: 23523026     Source Type: Journal    
DOI: 10.1016/S2352-3026(15)00020-4     Document Type: Article

References (33)

1. Thomas, DA, Kantarjian, H, Smith, TL, et al. Primary refractory and relapsed adult acute lymphoblastic leukemia: characteristics, treatment results, and prognosis with salvage therapy. Cancer 86 (1999), 1216–1230.
2. Tavernier, E, Boiron, JM, Huguet, F, et al. Outcome of treatment after first relapse in adults with acute lymphoblastic leukemia initially treated by the LALA-94 trial. Leukemia 21 (2007), 1907–1914.
3. Fielding, AK, Richards, SM, Chopra, R, et al. Outcome of 609 adults after relapse of acute lymphoblastic leukemia (ALL); an MRC UKALL12/ECOG 2993 study. Blood 109 (2007), 944–950.
4. Oriol, A, Vives, S, Hernández-Rivas, JM, et al. Outcome after relapse of acute lymphoblastic leukemia in adult patients included in four consecutive risk-adapted trials by the PETHEMA Study Group. Haematologica 95 (2010), 589–596.
5. Gökbuget, N, Stanze, D, Beck, J, et al. Outcome of relapsed adult lymphoblastic leukemia depends on response to salvage chemotherapy, prognostic factors, and performance of stem cell transplantation. Blood 120 (2012), 2032–2041.
6. 90Y labeled MAbs. Cancer Biother Radiopharm 14 (1999), 37–47.
7. Garcia-Barros, M, Paris, F, Cordon-Cardo, C, et al. Tumor response to radiotherapy regulated by endothelial cell apoptosis. Science 300 (2003), 1155–1159.
8. Sharkey, RM, Goldenberg, DM, Cancer radioimmunotherapy. Immunotherapy 3 (2011), 349–370.
9. Burke, JM, Jurcic, JG, Scheinberg, DA, Radioimmunotherapy for acute leukemia. Cancer Control 9 (2002), 106–113.
10. Hoelzer, D, Gokbuget, N, Chemoimmunotherapy in acute lymphoblastic leukemia. Blood Rev 26 (2012), 25–32.
11. Raponi, S, De Propris, MS, Intoppa, S, et al. Flow cytometric study of potential target antigens (CD19, CD20, CD22, CD33) for antibody-based immunotherapy in acute lymphoblastic leukemia: analysis of 552 cases. Leuk Lymphoma 52 (2011), 1098–1107.
12. Kantarjian, H, Thomas, D, Jorgensen, J, et al. Inotuzumab ozogamicin, an anti-CD22-calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 study. Lancet Oncol 13 (2012), 403–411.
13. Kreitman, RJ, Pastan, I, Antibody fusion proteins anti-CD22 recombinant immunotoxin moxetumomab pasudotox. Clin Cancer Res 17 (2011), 6398–6405.
14. Leonard, JP, Coleman, M, Ketas, JC, et al. Epratuzumab, a humanized anti-CD22 antibody, in aggressive non-Hodgkin's lymphoma: phase I/II clinical trial results. Clin Cancer Res 10 (2004), 5327–5334.
15. Micallef, IN, Maurer, MJ, Wiseman, GA, et al. Epratuzumab with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy in patients with previously untreated diffuse large B-cell lymphoma. Blood 118 (2011), 4053–4061.
16. Raetz, EA, Cairo, MS, Borowitz, MJ, et al. Chemoimmunotherapy reinduction with epratuzumab in children with acute lymphoblastic leukemia in marrow relapse: a Children's Oncology Group pilot study. J Clin Oncol 26 (2008), 3756–3762.
17. Advani, AS, McDonough, S, Coutre, S, et al. SWOG S0910: a phase 2 trial of clofarabine/cytarabine/epratuzumab for relapsed/refractory acute lymphocytic leukaemia. Br J Haematol 165 (2014), 504–509.
18. Carnahan, J, Stein, R, Qu, Z, et al. Epratuzumab, a CD22-targeting recombinant humanized antibody with a different mode of action from rituximab. Mol Immunol 44 (2007), 1331–1341.
19. Morschhauser, F, Kraeber-Bodere, F, Wegener, WA, et al. High rates of durable responses with anti-CD22 fractionated radioimmunotherapy: results of a multicenter, phase I/II study in non-Hodgkin's lymphoma. J Clin Oncol 28 (2010), 3709–3716.
20. 90Y-epratuzumab tetraxetan following R-CHOP in elderly DLBCL patients: a LYSA phase II prospective trial. Blood, 120, 2012, 906 (abstr).
21. 90Y-DOTA-hLL2: an agent for radioimmunotherapy of non-Hodgkin's lymphoma. J Nucl Med 44 (2003), 77–84.
22. Ferrer, L, Malek, E, Bodet-Milin, C, et al. Comparisons of dosimetric approaches for fractionated radioimmunotherapy of non-Hodgkin lymphoma. Q J Nucl Med Mol Imaging 56 (2012), 529–537.
23. Blumenthal, RD, Lew, W, Juweid, M, Alisauskas, R, Ying, Z, Goldenberg, DM, Plasma FLT3-L levels predict bone marrow recovery from myelosuprressive therapy. Cancer 88 (2000), 333–343.
24. Bertho, JM, Demarquay, C, Frick, J, et al. Level of FLT3-ligand in plasma: a possible new bio-indicator for radiation-induced aplasia. Int J Radiat Biol 77 (2001), 703–712.
25. 90Y-epratuzumab tetraxetan radioimmunotherapy in CD22+ Ph+ B-ALL: proof of principle. Eur J Haematol 91 (2013), 552–556.
26. 90Y-epratuzumab): do tumor targeting and dosimetry predict therapeutic response?. J Nucl Med 44 (2003), 2000–2018.
27. Milano, MT, Constine, LS, Okunieff, P, Normal tissue toxicity after small field hypofractionated stereotactic body radiation. Radiat Oncol, 3, 2008, 36.
28. Uckun, FM, Song, CW, Lack of CD24 antigen expression in B-lineage acute lymphoblastic leukemia is associated with intrinsic radiation resistance of primary clonogenic blasts. Blood 81 (1993), 1323–1332.
29. Findley, HW, Gu, L, Yeager, AM, Zhou, M, Expression and regulation of Bcl-2, Bcl-xl, and Bax correlate with p53 status and sensitivity to apoptosis in childhood acute lymphoblastic leukemia. Blood 89 (1997), 2986–2993.
30. Han, S, Brenner, JC, Sabolch, A, et al. Targeted radiosensitization of ETS fusion-positive prostate cancer through PARP1 inhibition. Neoplasia 15 (2013), 1207–1217.
31. Barbet, J, Bardiès, M, Bourgeois, M, et al. Radiolabeled antibodies for cancer imaging and therapy. Methods Mol Biol 907 (2012), 681–697.
32. 90Yttrium-ibritumomab tiuxetan consolidation of first remission in advanced-stage follicular non-Hodgkin lymphoma: updated results after a median follow-up of 7·3 years from the International, Randomized, Phase III First-Line Indolent trial. J Clin Oncol 31 (2013), 1977–1983.
33. 90Y-epratuzumab tetraxetan combined with anti-CD20 veltuzumab: a phase I study in patients with relapsed/refractory, aggressive non-Hodgkin lymphoma. Haematologica 99 (2014), 1738–1745.